Dallas, Texas 07/08/2013 (Financialstrend) – Novavax, Inc. (NASDAQ:NVAX) recently announced that Barclay A.Buck was appointed as the Chief Financial Officer and Senior Vice President of the company, with the decision coming into effect from June 24, 2013. From then on, the new CFO has taken over the responsibilities of effectively managing the treasury and of performing the major financial and related communications for the company. Prior to his appointment in Novavax, Mr. Phillips had been serving as the Chief Financial Officer at Micromet Inc., also acting as the Senior Vice President of the company.
Shares of Novavax, Inc. (NASDAQ:NVAX) closed at $2.62on Friday, recording a decline of 11.49 for the day. The stock price fluctuated during the day between $2.36 and $2.63, after opening at $2.39 on Friday. Shares of Novavax, Inc. (NASDAQ:NVAX)have a 52-week low price of $1.52 and a 52-week high price of $2.77.
As for the percentage of the company’s ownership structure, institutional owners hold around 45 percent of the total equity capital in Novavax, Inc. (NASDAQ:NVAX) and there are 152.46 million shares outstanding in the market. The company recorded an average volume of trading at 1.56 million shares per day.
Novavax, Inc. (NASDAQ:NVAX) is a biopharmaceutical company which develops recombinant vaccines. Novavax, Inc. (NASDAQ:NVAX) is based on a recombinant vaccine technology which includes virus-like particles (VLPs). Novavax, Inc.’s (NASDAQ:NVAX) products are genetically engineered three-dimensional nano structures, which contain the immunologically important recombinant proteins. Novavax, Inc.’s (NASDAQ:NVAX) research department focuses on a variety of infectious diseases. Novavax, Inc.’s (NASDAQ:NVAX) products have passed various clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus (RSV). Novavax, Inc. (NASDAQ:NVAX) is part of a Joint Venture (JV) with CPL Biologics Private Limited, which develops a genetically engineered rabies vaccine.CPL Biologics Private Limited is progressing with pre-clinical toxicology studies after completing the initial pre-clinical immunogenicity studies on this new vaccine.